Respiratory syncytial virus (RSV) poses a considerable, yet frequently enough overlooked, threat to adult health, intricate by underdiagnosis due to vague symptoms and limited diagnostic tools. A recent study published in The Lancet introduces a novel method for assessing RSV-related hospitalizations in adults,utilizing clinical data to reveal notable correlations between RSV activity and a rise in respiratory and cardiorespiratory hospital admissions.

RSV Severity in Adults

RSV presents a particular danger to older adults and individuals with chronic health issues, especially those who are frail or residing in nursing facilities. The CDC estimates that annually,RSV leads to approximately 60,000 to 160,000 hospitalizations among older adults,resulting in 6000 to 10,000 fatalities. Initial symptoms mirror a common cold, appearing 4 to 6 days post-exposure, and include a congested or runny nose, mild cough, slight fever, sore throat, sneezing, and headache.Severe infections can manifest as high fever, intense coughing, wheezing, rapid or labored breathing, and cyanosis (bluish skin discoloration).

Study Methods and Findings

“By leveraging high-quality surveillance data… our study provides a nuanced understanding of RSV’s impact on both respiratory and cardiorespiratory diseases.”

The study amassed clinical data spanning 1992 to 2021 from hospital records and insurance claims across 15 countries-Argentina, Brazil, Canada, Chile, Georgia, Germany, Greece, Ireland, Italy, Japan, Mexico, new Zealand, Poland, Spain, and the United States. the data encompassed respiratory and cardiorespiratory hospitalizations among adults aged 18-59, 60-70, and 75 and older. Researchers also incorporated methodologies from the Global Burden of Disease (GBD) study, emphasizing the comparative risk assessment framework.

Researchers applied generalized additive models to evaluate the relationship between RSV activity and hospitalizations from 2015 to 2019, factoring in trends, seasonality, meteorological factors, and influenza activity. They then determined the population attributable fraction (PAF) to quantify RSV-attributable hospitalizations.

The study’s findings underscored a significant association between RSV activity and increased hospitalizations for respiratory and cardiorespiratory conditions in adults. RSV-attributable hospitalization rates and PAFs varied among age groups and countries. Adults aged 75 and older showed the highest annual RSV-attributable hospitalization rates, ranging from 110.9 per 100,000 in Argentina to 1100.8 per 100,000 for cardiorespiratory hospitalizations in New zealand.Conversely, adults aged 18 to 59 in Spain exhibited the lowest RSV-attributable hospitalization rates for both respiratory and cardiorespiratory diseases, at 5.0 hospitalizations per 100,000.

These results highlight the significant impact of RSV infection and offer valuable global data on RSV incidence, aiding pharmacists and healthcare providers in making informed decisions about interventions and vaccinations for adults at risk.

The study authors concluded,”By leveraging high-quality surveillance data from 2015 onwards and adopting a comprehensive hospitalization analysis,our study provides a nuanced understanding of RSV’s impact on both respiratory and cardiorespiratory diseases. This holistic outlook is crucial for informing public health strategies-particularly whether and how to use new interventions-and advancing our knowledge of RSV’s broader health implications.”